During the last few years, a growing novel list of personalized therapies has been approved for the treatment of breast cancer including alpelisib targeting PI3K, talazoparib and olaparib that target germline BRCA mutated breast cancer, and abemaciclib as a cell cycle inhibitor for patients with high Ki67 [138]. Here, MKI67 is linked to breast carcinoma.